NicOx.... in attesa di.....

(Boursier.com) — Les actions Nicox ont été suspendues à 10h01 sur le marché parisien. Une suspension "à la demande de la société, dans l'attente de la publication d'un communiqué de presse et jusqu'à nouvel avis", selon la formule consacrée contenue dans l'avis Euronext. Le titre cotait 10,94 euros, en hausse de 3,4% au moment de la suspension.
 
SPERATE SOLO CHE NON SIA UN ANNUNCIO DI OPA PERCHE' IL CETRIOLO IN QUEL CASO SAREBBE GRANDE.CERTO CHE I MOVIMENTI PASSATI FANNO SOSPETTARE CHE L'IPOTESI SIA MOLTO FACILE E REALISTICA.SAREBBE DAVVERO UNA PRESA PER I FONDELLI ENORME
 
L'UNICA COSA CHE MI FA DUBITARE SULL'OPA E' CHE ,MI SEMBRA,CHE TALI OPERAZIONI VADANO COMUNICATE A MERCATI CHIUSI.MA POTREI RICORDARE MALE.
 
guly ha scritto:
SPERATE SOLO CHE NON SIA UN ANNUNCIO DI OPA PERCHE' IL CETRIOLO IN QUEL CASO SAREBBE GRANDE.CERTO CHE I MOVIMENTI PASSATI FANNO SOSPETTARE CHE L'IPOTESI SIA MOLTO FACILE E REALISTICA.SAREBBE DAVVERO UNA PRESA PER I FONDELLI ENORME
Clicca per allargare...

Se anche fosse, nessuno venderebbe le azioni a meno di 18 €, Garufi per primo.
 
ZERVIATE APPROVATO.

Press Release

Nicox receives FDA approval of ZERVIATE (cetirizine ophthalmic solution) 0.24%

  • First approved US NDA for Nicox
  • First topical ocular formulation of the antihistamine cetirizine
  • U.S. patent protection until at least 2030
  • Partnering discussions underway for U.S. commercialization rights
May 31, 2017 - release at 3:00 pm CET

Sophia Antipolis, France.


Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ZERVIATE (cetirizine ophthalmic solution 0.24%; formerly AC-170) the first topical ocular formulation of this well-known antihistamine, for the treatment of ocular itching associated with allergic conjunctivitis.

“Receiving approval from the U.S. FDA for ZERVIATE is a huge milestone for Nicox and partnering discussions are underway for U.S. commercialization rights,” commented Michele Garufi, Chairman and Chief Executive Officer of Nicox. “We expect to further solidify our position as a leading ophthalmic R&D company with the anticipated FDA decision on Vyzulta, which is licensed worldwide to Bausch + Lomb, and the expected commencement of Phase 2 clinical trials for both NCX 4251 and NCX 470. This is an exciting time for Nicox, and we look forward to keeping you updated on our progress.”

Following discussion with the AMF, the Company has requested the suspension of trading in Nicox shares today, Wednesday May 31, 2017. Trading is expected to recommence shortly after the issuance of this press release



Please find attached the complete press release



About Nicox

Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma. Nicox currently has an approved NDA product and another product at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com .
 
Communiqué de presse

Nicox reçoit l’approbation de la FDA pour ZERVIATE (solution ophtalmique de la cétirizine) 0,24%

  • Première approbation de mise sur le marché aux Etats-Unis pour Nicox
  • Première formulation oculaire topique de l’antihistaminique cétirizine
  • Couvert par brevet aux Etats-Unis jusqu’au moins 2030
  • Discussions en cours pour une licence des droits de commercialisation aux Etats-Unis
31 mai 2017 - diffusion à 15h00

Sophia Antipolis, France

Nicox S.A. (Euronext Paris : FR0013018124, COX, éligible PEA-PME), société internationale de R&D spécialisée en ophtalmologie, annonce aujourd'hui l'approbation par la FDA américaine (Food and Drug Administration) de la demande d'autorisation de mise sur le marché aux Etats-Unis (New Drug Application, NDA) pour ZERVIATE (solution ophtalmique de la cétirizine 0,24%; précédemment AC-170), la première formulation oculaire topique de cet antihistaminique bien connu pour le traitement du prurit oculaire associé aux conjonctivites allergiques.

“L’approbation du ZERVIATE par la FDA américaine est une étape considérable pour Nicox et des discussions de partenariat sont en cours pour la licence des droits de commercialisation aux Etats-Unis,” a commenté Michele Garufi, Président Directeur Général de Nicox. “Nous nous attendons à renforcer la position de notre société de R&D leader dans le domaine de l’ophtalmologie avec d'une part la décision de la FDA pour Vyzulta, produit licencié mondialement à Bausch + Lomb et d'autre part le projet de lancement d’études cliniques de phase 2 pour NCX 4251 et NCX 470. C’est une période enthousiasmante pour Nicox et nous vous tiendrons informés de nos progrès.”

Après discussion avec l'AMF, la Société a demandé la suspension de la cotation de l'action Nicox aujourd'hui 31 mai 2017. La cotation devrait reprendre rapidement après la diffusion du communiqué de presse.
 
ora spero solo che non venga interpretata male l'approvazione per il fatto,mi sembra,che si dovranno dare piu azioni agli yankee?come era il discorso.
 
You must log in or register to reply here.

Similar threads

DickSIM
Pharma e Biotech - Europa NicOx..aspettando non si sa cosa..senza il NET-ZOHAR!!
2 3 4
Risposte
35
Visite
5.627
DickSIM
DickSIM

Users who are viewing this thread

Total: 1 (members: 0, guests: 1)
Back
Alto